Goldman Sachs Analyst Reinstates Sell Rating on DBV Technologies Amid VP Treatment Risks
On May 28, Goldman Sachs analyst Rajan Sharma reinstated his sell rating on DBV Technologies S.A. (NASDAQ:DBVT) and set the price target at $7.25.
Posts Tagged ‘NASDAQ:DBVT’
Why These 15 Healthcare Stocks Are Surging in 2025
After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year.
DBV Technologies S.A. (NASDAQ:DBVT) Q2 2024 Earnings Call Transcript
DBV Technologies S.A. (NASDAQ:DBVT) Q2 2024 Earnings Call Transcript July 30, 2024DBV Technologies S.A. misses on earnings expectations.
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript
Operator: Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results and Business Update Conference Call.
DBV Technologies S.A. (NASDAQ:DBVT) Q3 2023 Earnings Call Transcript
Operator: Welcome to the DBV's Third Quarter Financial Results and Business and Regulatory Update Conference Call.
DBV Technologies S.A. (NASDAQ:DBVT) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the DBV Technologies Second Quarter Financial Results Conference Call. My name is Vaishnavi, and I am the operator for this call.
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2022 Earnings Call Transcript
Operator: Good day, and welcome to the DBV Technologies Full Year 2022 Financial Results Conference Call. Please note this event is being recorded.
5 Best Medical Stocks Under $10
In this article, we will be looking at the 5 best medical stocks under $10.
DBV Technologies SA (DBVT) Fell Out Of Favor With Hedge Funds
In this article you are going to find out whether hedge funds think DBV Technologies SA (NASDAQ:DBVT) is a good investment right now.
Here is What Hedge Funds Think About DBV Technologies SA (DBVT)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file ...
Hedge Funds Are Dumping DBV Technologies SA – ADR (DBVT)
How do we determine whether DBV Technologies SA - ADR (NASDAQ:DBVT) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors...
Here’s What Hedge Funds Think About DBV Technologies SA – ADR (DBVT)
Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could...
Did Hedge Funds Drop The Ball On DBV Technologies SA – ADR (DBVT) ?
While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war...
Market Movers Today: Tetraphase Pharmaceuticals Inc (TTPH), Twilio Inc (TWLO), Genesco Inc. (GCO), Nektar Therapeutics (NKTR), and More
Tetraphase Pharmaceuticals Inc's Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to...
13G Filing: Perceptive Advisors and DBV Technologies SA – ADR (DBVT)
Please follow Perceptive Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Perceptive Advisors or update its stock holdings...
DBV Technologies SA – ADR (DBVT): Smart Money Is Slowly Coming Back
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Third Point because we determined that some of the stocks...
5 Stocks That Healthcare Fund Deerfield Management Was Buying in Q2
Founded by James E. Flynn in 2000, Deerfield Management has grown to become one of the premier healthcare-focused investment management companies today.
The Most Popular French Stocks Among Hedge Funds
French president François Hollande was recently quoted as saying “ça va mieux” of his country's economy, which means that things are improving.
Venrock’s VHCP Management’s Top Picks For 2016
At Insider Monkey, we look at the weighted average returns of the long positions a fund indicates in its 13F filings, in companies with a market cap greater than $1 billion, ...
Here is What Hedge Funds Think About DBV Technologies SA – ADR (DBVT)
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end...
Baker Bros. Relentlessly Adding Shares Of One Biotech, Going Activist On Another
Julian Baker and Felix Baker’s Baker Bros. Advisors continues to relentlessly add shares to its position in Seattle Genetics, Inc. (NASDAQ:SGEN).
Baker Bros. Advisors Buys More DBV Technologies S.A. (DBVT); Visium Asset Management Goes Long On Pacira Pharmaceuticals Inc. (PCRX)
According to a freshly-amended 13G filing with the SEC, Baker Bros. Advisors LP, founded by Julian Baker and Felix Baker, revealed it owns 15.1% of DBV Technologies S.A.
Avalanche Biotechnologies Inc (AAVL), Anacor Pharmaceuticals Inc (ANAC), DBV Technologies, Boulogne-Billancourt (DBVT): Among Venrock’s Top Succesful Biotech Plays
Venrock Healthcare Capital Partners is a fund that is focused entirely on the healthcare sector, mainly on the biotech sector.
